Yüklüyor......
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
BACKGROUND: The continuum of anti-HER2 agents is a standard treatment of HER2 + metastatic breast cancer (MBC). This study evaluated the efficacy of lapatinib plus vinorelbine in patients progressed on both trastuzumab and lapatinib treatments. METHODS: A total of 149 patients were randomly assigned...
Kaydedildi:
| Yayımlandı: | Br J Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6964682/ https://ncbi.nlm.nih.gov/pubmed/31690831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0618-z |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|